• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Sohini Chowdhury, 2011

Sohini Chowdhury, 2011



Michael J Fox

Michael J Fox



Total Views
Views on SlideShare
Embed Views



14 Embeds 182

http://disruptiveinnovationsinclinicaltrials.blogspot.com 146
http://disruptiveinnovationsinclinicaltrials.blogspot.co.uk 8
http://disruptiveinnovationsinclinicaltrials.blogspot.com.br 5
http://disruptiveinnovationsinclinicaltrials.blogspot.in 5
http://disruptiveinnovationsinclinicaltrials.blogspot.com.au 4
http://disruptiveinnovationsinclinicaltrials.blogspot.nl 3
http://disruptiveinnovationsinclinicaltrials.blogspot.com.es 2
http://disruptiveinnovationsinclinicaltrials.blogspot.ca 2
http://disruptiveinnovationsinclinicaltrials.blogspot.be 2
http://disruptiveinnovationsinclinicaltrials.blogspot.pt 1
http://disruptiveinnovationsinclinicaltrials.blogspot.fr 1
http://disruptiveinnovationsinclinicaltrials.blogspot.co.il 1
http://disruptiveinnovationsinclinicaltrials.blogspot.co.at 1
http://disruptiveinnovationsinclinicaltrials.blogspot.gr 1


Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment

    Sohini Chowdhury, 2011 Sohini Chowdhury, 2011 Presentation Transcript

    • Public-Private Partnership Model: The Parkinson’s Progression Markers Initiative •Sohini Chowdhury, Vice President, Research Partnerships Sept 16, 2011
    • Parkinson’s is a global disease and prevalence is growing  Parkinson’s disease (PD) is a progressive neurodegenerative disease that affects nearly six million worldwide.  PD prevalence is expected to grow sizably over the next 25 years as the proportion of older citizens continues to increase globally.  Current therapies address mild/moderate motor symptoms  There is currently no therapy proven to modify – slow or halt – the progression of the disease. 2
    • Drug development is a lengthy and costly process Takes ~15 years for drug therapy to go through R&D and get to market ~8 of those years are spent in clinical testing 3
    • Clinical testing of PD therapies is challenging  Obstacles include: • Current trial paradigm requires large number of subjects • Efficacy testing is a long process, diminishing patent value • Reliance on clinical measures alone confound trial interpretation • There are no biological indications of underlying disease that complement clinical changes Increases risk for pharma, the main sponsors of therapeutic trials
    • The Parkinson’s Progression Markers Initiative (PPMI) PPMI is a ground-breaking clinical study that aims to accelerate PD drug development by identifying biomarkers of Parkinson’s Disease
    • Critical to PPMI’s success is recruiting a cohort of 600 21 sites in Europe and US are recruiting subjects; soon to be expanded to Australia 6
    • Various groups provide input/management of study facets 7
    • Industry is a valuable partner
    • A strong emphasis on standardization and sharing SOPs 9
    • A strong emphasis on recruitment PPMI Enrollment Status As of Sept 2011 10
    • Data made available and shared in real-time via study website 11